Kyowa Kirin Co Ltd
TSE:4151
Kyowa Kirin Co Ltd
Total Receivables
Kyowa Kirin Co Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kyowa Kirin Co Ltd
TSE:4151
|
Total Receivables
¥157B
|
CAGR 3-Years
15%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
0%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Total Receivables
¥735.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
4%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Total Receivables
¥624.2B
|
CAGR 3-Years
30%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Total Receivables
¥518.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Total Receivables
¥350.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Total Receivables
¥657.6B
|
CAGR 3-Years
19%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
|
Kyowa Kirin Co Ltd
Glance View
Kyowa Kirin Co., Ltd. stands as a notable presence in the global pharmaceutical landscape, having evolved from its roots in Japan into a significant force in medical innovation. This company, originally established from the merger of Kyowa Hakko Kogyo and Kirin Pharma, focuses on the development and commercialization of biopharmaceuticals that tackle complex medical conditions, primarily within the fields of oncology, nephrology, immunology, and neurology. With a strategy deeply rooted in research and development, Kyowa Kirin harnesses its proprietary antibody technologies and innovative approaches to deliver therapeutic solutions, fostering partnerships that expand its impact and reach. Their commitment to scientific progress is supplemented by a robust pipeline of investigational drugs, demonstrating their dedication to addressing unmet medical needs. Kyowa Kirin operates primarily on a business model that derives revenues from the successful commercialization of its pharmaceutical products. The company navigates the delicate balance between high-stakes investment in R&D and the potential high rewards that come from developing effective new treatments. By consistently bringing innovative therapies to market, they generate revenue through direct sales, collaborations, and licensing agreements within both domestic and international spheres. Additionally, their strategic alliances with biotech firms and research institutions globally enable them to enhance their R&D capabilities, ensuring a steady flow of new drugs that sustain their growth and solidify their competitive edge in the highly regulated and competitive pharmaceutical sector.
See Also
What is Kyowa Kirin Co Ltd's Total Receivables?
Total Receivables
157B
JPY
Based on the financial report for Dec 31, 2024, Kyowa Kirin Co Ltd's Total Receivables amounts to 157B JPY.
What is Kyowa Kirin Co Ltd's Total Receivables growth rate?
Total Receivables CAGR 10Y
0%
Over the last year, the Total Receivables growth was 32%. The average annual Total Receivables growth rates for Kyowa Kirin Co Ltd have been 15% over the past three years , -16% over the past five years .
You don't have any saved screeners yet